Note: Ingredients listed on restricted chemical lists
EC/CAS
236-675-5/13463-67-7
Name of the chemical
Reaction mass of titanium dioxide and silver chloride
Concentration
<0.5
EC/CAS
204-617-8/123-31-9
Name of the chemical
1,4-Dihydroxybenzol (790/2009)
Concentration
<0.05
General Information
Version
7.00
Revision date
2016-07-14
Product name
3M Clinpro Sealant
1.2.2. Uses advised against
For use only by dental professionals
Emergency telephone
+44 (0)1344 858 000
Icons in SDS
Company Information
company name
3M United Kingdom PLC
e-mail address of the competent person responsible for the Safety Data Sheet
tox.uk@mmm.com
GHS Information
Signal word
WARNING
Hazard Codes
Hazard statements (CLP)
H317
Hazard statements
Code
Statements
H317
May cause an allergic skin reaction
Section 2
SECTION 2: Hazards identification
Regulation (EC) No. 1272/2008 Classification of the substance or mixture
Signal word
WARNING.
Hazard pictograms
GHS07 (Exclamation mark) | Ingredients: Ingredient CAS Nbr % by Wt 2,2'-ethylenedioxydiethyl dimethacrylate 109-16-0 40 - 50 (1-methylethylidene)bis[4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)] 1565-94-2 40 - 50 bismethacrylate
Hazard statements
H317 May cause an allergic skin reaction.
Prevention
P280E Wear protective gloves.
Response
P333 + P313 If skin irritation or rash occurs: Get medical advice/attention.
2.3 Other hazards
For information on hazards and safe use, please consider the corresponding sections of this document.
2.1 Classification of the substance or mixture
CLP REGULATION (EC) No 1272/2008 This product is a medical device as defined in Directive 93/42/EEC (MDD), which is invasive or used in direct physical contact with the human body, and therefore is exempt from the requirements of classification and labelling according to Regulation (EC) No. 1272/2008 (CLP; Article 1, paragraph 5). Although not required, the classification and label information, as applicable, is provided below. CLASSIFICATION: Skin Sensitization, Category 1B - Skin Sens. 1B; H317 For full text of H phrases, see Section 16.
